(Q58049799)

1

0 references

Annabelle L. Rodd

2

0 references

Michelle M. Tang

3

0 references

Tom C. Karagiannis

Cellular and Molecular Life Sciences

5

0 references

publication date

17 May 2011

0 references

published in

0 references

volume

68

0 references

page(s)

4101-4114

0 references

issue

24

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00018-011-0727-1

0 references

cites work

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Histone deacetylase inhibitors in lymphoma and solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Nonhistone protein acetylation as cancer therapy targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Rational combinations using HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Development of vorinostat: current applications and future perspectives for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

The epigenetic modifier, valproic acid, enhances radiation sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

The anthracycline antineoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

gammaH2AX: a sensitive molecular marker of DNA damage and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Properties of a clonal muscle cell line from rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Cardiac hypertrophy: the good, the bad, and the ugly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

The epidemiology of heart failure: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Lifetime Risk for Developing Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Growth and aging: a common molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Rapamycin decelerates cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

H2AX: functional roles and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

DNA damage is an early event in doxorubicin-induced cardiac myocyte death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Interaction of daunomycin with acetylated chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0727-1

Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

21 January 2018

1 reference

12 December 2020

Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart

1 reference

12 December 2020

Anthracyclines in the treatment of cancer. An overview

1 reference

12 December 2020

Human heart cytosolic reductases and anthracycline cardiotoxicity

1 reference

12 December 2020

Quantification of gammaH2AX foci in response to ionising radiation.

1 reference

12 December 2020

Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response

1 reference

12 December 2020

Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.

1 reference

12 December 2020

Evaluation of the spatial distribution of gammaH2AX following ionizing radiation

1 reference

12 December 2020

The anthracyclines: will we ever find a better doxorubicin?

1 reference

12 December 2020

Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.

1 reference

12 December 2020